Business
OSE Immunotherapeutics: A Clear Strategy, Balanced Governance, and a Firm Course toward Value Creation
OSE Immunotherapeutics: A Clear Strategy, Balanced Governance, and a Firm Course toward Value Creation NANTES, France – September 4, 2025, 6 p.m. CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) reaffirms its strategic commitment to value creation ahead of the September 30 Annual General Meeting. The Company is focused on developing innovative therapies in immuno-oncology and immuno-inflammation, supported by a robust and differentiated portfolio, a cutting-edge research platform
About this update from Ose Immunotherapeutics Sa
[{"type":"image","alt":"OSE Immunotherapeutics","displaySize":"","headline":null,"caption":"OSE Immunotherapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":100,"url":"https://media.zenfs.com/en/globenewswire.com/bca4e9e3611afcc1a4e99230a01fa8eb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/h55Oot7mWh39J7Yvj1GueA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/bca4e9e3611afcc1a4e99230a01fa8eb","width":300,"height":100}},"lazy":false},{"type":"text","content":"OSE Immunotherapeutics: A Clear Strategy, Balanced Governance, and a Firm Course toward Value Creation","length":102,"tagName":"p"},{"type":"text","content":"NANTES, France – September 4, 2025, 6 p.m. CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) reaffirms its strategic commitment to value creation ahead of the September 30 Annual General Meeting. The Company is focused on developing innovative therapies in immuno-oncology and immuno-inflammation, supported by a robust and differentiated portfolio, a cutting-edge research platform, and stable, balanced governance to ensure continuity in its scientific, financial, and human endeavors.","length":502,"tagName":"p"},{"type":"text","content":"OSE Strategy 2025–2028: continuing the growth trajectory driven by the company’s core strengths","length":95,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Continue developing a balanced pipeline of partnered assets and proprietary products such as Tedopi® (oncology) and Lusvertikimab (inflammation), targeting indications with high unmet medical need.","length":197,"tagName":"p"}]},{"val":[{"type":"text","content":"Advance innovative research programs in next-generation immunotherapy to feed OSE’s product and partnership pipeline.","length":117,"tagName":"p"}]},{"val":[{"type":"text","content":"Ensure balanced, rigorous, and differentiated financing based on asset maturity, with priority given to supporting the ongoing Phase 3 development of Tedopi® (launched in September 2024) and the complementary Phase 2b study for Lusvertikimab.","length":242,"tagName":"p"}]},{"val":[{"type":"text","content":"Rely on stable and balanced governance composed of experts in the pharmaceutical and financial sectors.","length":103,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":65...